NCT06129084View on ClinicalTrials.gov

A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

RecruitingOBSERVATIONAL
Enrollment

260

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Metastatic Bladder CancerMetastatic Urothelial Carcinoma
Interventions
GENETIC

FGFR Testing

Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.

Trial Locations (7)

T2N 5G2

ACTIVE_NOT_RECRUITING

Arthur J.E Child Comprehensive Cancer Centre, Calgary

T6G 1Z2

ACTIVE_NOT_RECRUITING

Cross Cancer Institute, Edmonton

V5Z 4E6

RECRUITING

BC Cancer Agency, Vancouver

N6A 5W9

ACTIVE_NOT_RECRUITING

London Health Sciences Centre, London

K1H 8L6

ACTIVE_NOT_RECRUITING

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

ACTIVE_NOT_RECRUITING

Princess Margaret Cancer Centre, Toronto

G1R 2J6

ACTIVE_NOT_RECRUITING

CHU de Québec-Université Laval, Québec

All Listed Sponsors
collaborator

Vancouver Prostate Centre

OTHER

collaborator

Lady Davis Institute

OTHER

collaborator

Bladder Cancer Canada

UNKNOWN

lead

Bernie Eigl

OTHER

NCT06129084 - A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing | Biotech Hunter | Biotech Hunter